Daito Pharmaceutical Reports FY26 Revenue of 50.6 billion, Flat 0%
TOKYO, Jul 10 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) reported consolidated results for fiscal year 2026 ending May. Revenue was ¥50.6 billion (+0.0% YoY). operating profit was ¥3,
TOKYO, Jul 10 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) reported consolidated results for fiscal year 2026 ending May.
Revenue was ¥50.6 billion (+0.0% YoY). operating profit was ¥3,637 million (+38.8%). net profit attributable to shareholders was ¥3,161 million (+65.7%).
Total assets stood at ¥73.3 billion with an equity ratio of 72.2%. The company declared an annual dividend of ¥20 per share. The full-year forecast for the current fiscal year is revenue of ¥54.0 billion (+6.6%).
Financial results — FY2026/5 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥50,650M | +0.0% |
| Operating profit | ¥3,637M | +38.8% |
| Net profit | ¥3,161M | +65.7% |
Source: TDNet filing · Figures in millions of yen